Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

Cited by (1,000)

Items 101–200 of 1,000

1. Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson’s disease
   Sundaram, Saranya, Hughes, Rachel L., Peterson, Eric, Müller-Oehring, Eva M., Brontë-Stewart, Helen M., Poston, Kathleen L., Faerman, Afik, Bhowmick, Chloe, Schulte, Tilman · 2019 · Neuroscience & Biobehavioral Reviews
2. Treatment Options in the Modern Management of Parkinson Disease
   Anthony H.V. Schapira · 2007 · Archives of Neurology
3. Dementia in Parkinson's disease
   Hasmet Ayhan Hanagasi, Zeynep Tüfekçıoğlu, Murat Emre · 2017 · Journal of the Neurological Sciences
4. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients
   Aristide Merola, Maurizio Zibetti, Serena Angrisano, Laura Rizzi, Valeria Ricchi, Carlo Alberto Artusi, Michele Lanotte, Mario Giorgio Rizzone, Leonardo Lopiano · 2011 · Brain
5. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations
   Jennifer G. Goldman, Glenn T. Stebbins, Vy Dinh, Bryan A. Bernard, Douglas Merkitch, Leyla deToledo‐Morrell, Christopher G. Goetz · 2014 · Brain
6. Monitoring of 30 marker candidates in early Parkinson disease as progression markers
   Brit Mollenhauer, Johannes Zimmermann, Friederike Sixel‐Döring, Niels K. Focke, Tamara Wicke, Jens Ebentheuer, Martina Schaumburg, Elisabeth Lang, Ellen Trautmann, Henrik Zetterberg et al. · 2016 · Neurology
7. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
   Tai Ngọc Tran, Trang N. N. Vo, Karen P. Frei, Daniel Dung Truong · 2018 · Journal of Neural Transmission
8. Differences in MDS ‐ UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
   Matěj Škorvánek, Pablo Martínez‐Martín, Norbert Kovács, Mayela Rodríguez‐Violante, Jean‐Christophe Corvol, Pille Taba, Klaus Seppi, Oleg Semenovich Levin, Anette E. Schrag, Thomas Foltynie et al. · 2017 · Movement Disorders Clinical Practice
9. Mortality in Parkinson's disease: A 38‐year follow‐up study
   Bernadette Pinter, Anja Diem‐Zangerl, Gregor Karl Wenning, Christoph Scherfler, Willi Oberaigner, Klaus Seppi, Werner H Poewe · 2014 · Movement Disorders
10. Droxidopa for the S hort‐ T erm T reatment of S ymptomatic N eurogenic O rthostatic H ypotension in P arkinson's D isease (n OH 306 B )
    Robert A. Hauser, Stuart Isaacson, Jerome P. Lisk, L. Arthur Hewitt, Gerry J. Rowse · 2014 · Movement Disorders
11. Effects of cognitive function on gait and dual tasking abilities in patients with Parkinson’s disease suffering from motor response fluctuations
    Meir Plotnik, Yaacov Dagan, Tanya Gurevich, Nir Giladi, Jeffrey M. Hausdorff · 2010 · Experimental Brain Research
12. Long‐term outcomes of surgical therapies for Parkinson's disease
    M. Rodríguez-Oroz, E. Moro, P. Krack · 2012 · Movement Disorders
13. Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up
    M. Hariz, P. Krack, F. Alesch, L. Augustinsson, A. Bosch, R. Ekberg, F. Johansson, B. Johnels, B. Meyerson, J. N'guyen et al. · 2007 · Journal of Neurology Neurosurgery & Psychiatry
14. Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?
    Claire McDonald, Julia L. Newton, David John Burn · 2016 · Movement Disorders
15. Levodopa-Associated Dyskinesia Risk Among Parkinson Disease Patients in Olmsted County, Minnesota, 1976-1990
    Jay A. van Gerpen, Neeraj Kumar, James H. Bower, Stephen D. Weigand, J. Eric Ahlskog · 2006 · Archives of Neurology
16. Back to the tubule: microtubule dynamics in Parkinson’s disease
    Laura Pellegrini, Andrea Wetzel, Simone Grannò, George Heaton, Kirsten Harvey · 2016 · Cellular and Molecular Life Sciences
17. In‐patient multidisciplinary rehabilitation for Parkinson's disease: A randomized controlled trial
    Marco Monticone, Emilia Ambrosini, Alessandro Laurini, Barbara Rocca, Calogero Foti · 2015 · Movement Disorders
18. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease
    Troeung, Lakkhina, Egan, Sarah J., Gasson, Natalie · 2013 · PLoS ONE
19. Serotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
    CARTA, M, CARLSSON, T, MUNOZ, A, KIRIK, D, BJORKLUND, A · 2008 · Progress in brain research
20. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting
    Omidreza Jafarieh, Shadab Md, Mushir Ali, Sanjula Baboota, Jasjeet Kaur Sahni, Bhavna Kumar, Aseem Bhatnagar, Javed Ali · 2014 · Drug Development and Industrial Pharmacy
21. Validation of the non-motor symptoms questionnaire (NMS-Quest)
    Silvia Ríos Romenets, Christina M. Wolfson, Christos Galatas, Amélie Pelletier, Robert Altman, Lisa Wadup, Ronald B. Postuma · 2011 · Parkinsonism & Related Disorders
22. A 12-year population-based study of freezing of gait in Parkinson's disease
    Elin Bjelland Forsaa, Jan Otto Larsen, Tore Wentzel‐Larsen, Guido Werner Alves · 2014 · Parkinsonism & Related Disorders
23. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
    C. Warren Olanow, Stewart Alan Factor, Alberto Javier Espay, Robert A. Hauser, Holly A. Shill, Stuart Isaacson, Rajesh Pahwa, Mika Leinonen, Parul Bhargava, Ken Sciarappa et al. · 2019 · The Lancet Neurology
24. New Sensor and Wearable Technologies to Aid in the Diagnosis and Treatment Monitoring of Parkinson's Disease
    Mariana H.G. Monje, Guglielmo Foffani, Jose Angel Obeso, Álvaro Sánchez‐Ferro · 2019 · Annual Review of Biomedical Engineering
25. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: Concept and standards of the EARLYSTIM-study
    Günther Deuschl, Michael W.M. Schüpbach, Karina Knudsen, Marcus O. Pinsker, Philippe Cornu, Jörn Rau, Yves Agid, Carmen Schade‐Brittinger · 2012 · Parkinsonism & Related Disorders
26. Systematic Review of the Epidemiology of Urinary Incontinence and Detrusor Overactivity among Patients with Neurogenic Overactive Bladder
    A. Ruffion, David Manuel Castro-Diaz, Hetal Patel, Kristin M. Khalaf, Ahunna Onyenwenyi, DENISE R. GLOBE, C LeReun, Mamuka Teneishvili, Meredith Edwards · 2013 · Neuroepidemiology
27. Early Parkinson’s disease and non-motor issues
    К. Ray Chaudhuri, Yogini Naidu · 2008 · Journal of Neurology
28. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people
    Barbara Jacquelyn Sahakian, Annette Beatrix Brühl, Jennifer Louise Cook, Clare Killikelly, George Savulich, Thomas Piercy, Sepehr Hafizi, Jesús Pérez, Emilio Fernández-Egea, John Suckling et al. · 2015 · Philosophical Transactions of the Royal Society B Biological Sciences
29. Levodopa: A new look at an old friend
    C. Warren Olanow, Fabrizio Stocchi · 2017 · Movement Disorders
30. Late-stage Parkinson’s disease: the Barcelona and Lisbon cohort
    Miguel M Coelho, Marı́a José Martı́, EDUARDO S. TOLOSA, Joaquim José Ferreira, Francesc Valldeoriola, Mário Miguel Rosa, Cristina Sampaio · 2010 · Journal of Neurology
31. Effects of Sleep Disorders on the Non-Motor Symptoms of Parkinson Disease
    Ariel B. Neikrug, Jeanne E. Maglione, Lianqi Liu, Loki Natarajan, Julie A. Avanzino, Jody Corey‐Bloom, Barton W. Palmer, José S. Loredo, Sonia Ancoli‐Israel · 2013 · Journal of Clinical Sleep Medicine
32. Challenges of modifying disease progression in prediagnostic Parkinson's disease
    David Salat, Alastair John Noyce, Anette E. Schrag, EDUARDO S. TOLOSA · 2016 · The Lancet Neurology
33. Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease
    Santiago Perez‐Lloret, Olivier Rascol · 2010 · CNS Drugs
34. Parkinson disease: an update.
    John D. Gazewood, Danielle Richards, Karl T Clebak · 2013 · PubMed
35. Psychiatric aspects of Parkinson’s disease
    Sandeep Grover, Mansi P. Somaiya, Santhosh Kumar, Ajit Avasthi · 2014 · Journal of Neurosciences in Rural Practice
36. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients
    Roberto Erro, Marina Picillo, Carmine Vitale, Marianna Amboni, Marcello Moccia, Katia Longo, Autilia Cozzolino, Flavio Giordano, Anna De Rosa, Giuseppe De Michele et al. · 2012 · Journal of Neurology Neurosurgery & Psychiatry
37. How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
    P. Mahlknecht, T. Foltynie, P. Limousin, W. Poewe · 2022 · Movement Disorders
38. New treatments for levodopa‐induced motor complications
    Olivier Rascol, Santiago Perez‐Lloret, Joaquim José Ferreira · 2015 · Movement Disorders
39. Non-motor symptoms of Parkinson's disease A review…from the past
    Pedro Ruiz, К. Ray Chaudhuri, Pablo Martínez‐Martín · 2014 · Journal of the Neurological Sciences
40. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
    Dhanya Vijayakumar, Joseph J. Jankovic · 2016 · Drugs
41. Episodic recognition memory and the hippocampus in Parkinson's disease: A review
    Tanusree Das, Jaclyn Joyce Hwang, Kathleen L. Poston · 2018 · Cortex
42. Milestones in gait, balance, and falling
    John G. Nutt, Fay Bahling Horak, Bastiaan R. Bloem · 2011 · Movement Disorders
43. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease
    Papapetropoulos, Spiridon, Katzen, Heather, Schrag, Anette, Singer, Carlos, Scanlon, Blake K, Nation, Daniel, Guevara, Alexandra, Levin, Bonnie · 2008 · BMC Neurology
44. Clinical syndromes: Parkinsonian gait
    Georg Ebersbach, Caroline Moreau, Florin Gandor, Luc Defebvre, David Devos · 2013 · Movement Disorders
45. Spinal Cord Stimulation Therapy for Gait Dysfunction in Advanced Parkinson's Disease Patients
    Olivia Samotus, Andrew G. Parrent, Mandar Jog · 2018 · Movement Disorders
46. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia
    Myriam Heiman, Adrian M Heilbut, Veronica Francardo, Ruth Kulicke, Robert J. Fenster, Eric D. Kolaczyk, Jill P. Mesirov, Dalton James Surmeier, Maria Angela Cenci, Paul Greengard · 2014 · Proceedings of the National Academy of Sciences
47. Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: A cross-sectional study of patients with Parkinson’s disease and related neurological conditions
    Tariq Saleem, Irene J Higginson, К. Ray Chaudhuri, Anne Martin, Rachel Burman, P. Nigel Leigh · 2012 · Palliative Medicine
48. Neuropsychiatric Symptoms in Parkinson’s Disease
    Dag Aarsland, Milica Gregorič Kramberger · 2015 · Journal of Parkinson s Disease
49. Mortality in Parkinson's disease: A 20‐year follow‐up study
    Anja Diem‐Zangerl, Klaus Seppi, Gregor Karl Wenning, Eugen Trinka, Gerhard N. Ransmayr, Wilhelm Oberaigner, Werner H Poewe · 2009 · Movement Disorders
50. Consensus on the Definition of Advanced Parkinson’s Disease: A Neurologists-Based Delphi Study (CEPA Study)
    M. R. Luquín, Jaime Kulisevsky, Pablo Martínez‐Martín, Pablo Mir, EDUARDO S. TOLOSA · 2017 · Parkinson s Disease
51. Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis
    Stewart Alan Factor, Nelson Kyle Steenland, Donald S. Higgins, Eric Molho, Denise M. Kay, Jennifer S. Montimurro, A. R. Rosen, Cyrus P. Zabetian, Haydeh Payami · 2010 · Journal of Neurology Neurosurgery & Psychiatry
52. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: Frequent but mild
    Bernd Müller, Jan Petter Larsen, Tore Wentzel‐Larsen, GEIR OLVE SKEIE, Ole‐Bjørn Tysnes, for The Parkwest Study Group · 2010 · Movement Disorders
53. Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease
    Hengjun J. Kim, Sang Joon Kim, Ho Sung Kim, Choong Gon Choi, Namkug Kim, Seungbong Han, Eun Hye Jang, Sun Ju Chung, Chong Sik Lee · 2013 · Neuroscience Letters
54. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms
    Rubens Gisbert Cury, Ricardo Galhardoni, Erich Talamoni Fonoff, Santiago Perez‐Lloret, Maria Gabriela dos Santos Ghilardi, Egberto Reis Barbosa, Manoel Jacobsen Teixeira, Daniel Ciampi de Andrade · 2015 · European Journal of Pain
55. Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease
    Marina Picillo, Marianna Amboni, Roberto Erro, Katia Longo, Carmine Vitale, Marcello Moccia, Angela Pierro, Gabriella Santangelo, Anna De Rosa, Giuseppe Michele et al. · 2013 · Journal of Neurology
56. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models
    Zhenqiang Zhang, Christian Hölscher · 2019 · Peptides
57. Oil based nanocarrier system for transdermal delivery of ropinirole: A mechanistic, pharmacokinetic and biochemical investigation
    Azeem, Adnan, Talegaonkar, Sushama, Negi, Lalit M., Ahmad, Farhan J., Khar, Roop K., Iqbal, Zeenat · 2012 · International Journal of Pharmaceutics
58. Management of Motor and Non-Motor Symptoms in Parkinson’s Disease
    Fabienne Sprenger, Werner H Poewe · 2013 · CNS Drugs
59. Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease
    Karlijn J. Doorn, Paul John Lucassen, H. W. G. M. Boddeke, Marloes Prins, Henk W. Berendse, Benjamin Drukarch, Anne‐Marie van Dam · 2012 · Progress in Neurobiology
60. Histone Methylation Regulation in Neurodegenerative Disorders
    Balapal S. Basavarajappa, Shivakumar Subbanna · 2021 · International Journal of Molecular Sciences
61. Mortality in Parkinson's disease, a 20‐year follow‐up study
    Anja Diem‐Zangerl, Klaus Seppi, Wilhelm Oberaigner, Werner H Poewe · 2010 · Movement Disorders
62. MRI biomarkers of motor and non-motor symptoms in Parkinson's disease
    Sephira G. Ryman, Kathleen L. Poston · 2019 · Parkinsonism & Related Disorders
63. Clinical measures of progression in Parkinson's disease
    Werner H Poewe · 2009 · Movement Disorders
64. Motor and non-motor symptoms of 1453 patients with Parkinson's disease: Prevalence and risks
    Asako Yoritaka, Yasushi Shimo, Masashi Takanashi, Jiro Fukae, Taku Hatano, Toshiki Nakahara, Nobukazu Miyamato, Takao Urabe, Hideo Mori, Nobutaka Hattori · 2013 · Parkinsonism & Related Disorders
65. Mortality from Parkinson's disease: A population‐based prospective study (NEDICES)
    Ignacio J. Posada, Julián Benito‐León, Elan D. Louis, Rocío Trincado, Alberto Villarejo‐Galende, María José Medrano, Félix Bermejo‐Pareja · 2011 · Movement Disorders
66. Motor complications in Parkinson's disease: Ten year follow‐up study
    Iria Cabo López, Pedro Ruiz, Silvia Vázquez Fernández del Pozo, Vicenta Sánchez Bernardos · 2010 · Movement Disorders
67. Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities
    C. Warren Olanow, Paolo Calabresi, Jose Angel Obeso · 2020 · Movement Disorders
68. A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging
    Yashar Zeighami, Seyed‐Mohammad Fereshtehnejad, Mahsa Dadar, D. Louis Collins, Ronald B. Postuma, Bratislav Mišić, Alain Dagher · 2017 · NeuroImage
69. Effects of Stochastic Vestibular Galvanic Stimulation and LDOPA on Balance and Motor Symptoms in Patients With Parkinson's Disease
    Ghazaleh Samoudi, Maria Jivegård, Ajitkumar P. Mulavara, Filip Bergquist · 2014 · Brain stimulation
70. Old and new challenges in Parkinson's disease therapeutics
    Ana O. Pires, Fábio Gabriel Teixeira, Bárbara Mendes-Pinheiro, Sofia Cravino Serra, Nuno Sousa, António José Salgado · 2017 · Progress in Neurobiology
71. Levodopa-related wearing-off in Parkinson's disease: identification and management
    Rajesh Pahwa, Kelly E. Lyons · 2009 · Current Medical Research and Opinion
72. Balance in Parkinson's disease under static and dynamic conditions
    Antonio Nardone, Marco Schieppati · 2006 · Movement Disorders
73. Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
    Naomi P. Visanji, Jordi Gómez-Ramírez, Tom H. Johnston, Donna Pires, Valerie Voon, Jonathan M. Brotchie, Susan Helen Fox · 2006 · Movement Disorders
74. Prevalence of non motor features in a cohort of Parkinson's disease patients
    Eman Mohamed Khedr, Noha Abo Elfetoh, Hosam Khalifa, Mohamed Ahmed, Khaled Elbeh · 2012 · Clinical Neurology and Neurosurgery
75. Mortality and quality of death certification in a cohort of patients with Parkinson’s disease and matched controls in North Wales, UK at 18 years: a community-based cohort study
    Peter Hobson, Jolyon Meara · 2018 · BMJ Open
76. Treatment of advanced Parkinson's disease
    Juan C. Giugni, Michael S. Okun · 2014 · Current Opinion in Neurology
77. Gait and postural disorders in parkinsonism: a clinical approach
    Cecilia Raccagni, Jorik H. Nonnekes, Bastiaan R. Bloem, Marina Peball, Christian Boehme, Klaus Seppi, Gregor Karl Wenning · 2019 · Journal of Neurology
78. The morbid anatomy of dementia in Parkinson’s disease
    Michail E. Kalaitzakis, R. K. B. Pearce · 2009 · Acta Neuropathologica
79. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease
    Thomas H. Müller, Hermann Russ · 2006 · Expert Opinion on Pharmacotherapy
80. Hospitalization in Parkinson disease: A survey of National Parkinson Foundation Centers
    Kelvin L. Chou, Jorge Zamudio, Peter N. Schmidt, Catherine C. Price, Sotirios Andreas Parashos, Bastiaan R. Bloem, Kelly E. Lyons, Chadwick W. Christine, Rajesh Pahwa, Ivan G. Bodis-Wollner et al. · 2011 · Parkinsonism & Related Disorders
81. Medical Management of Parkinson’s Disease
    Elmyra V. Encarnacion, Robert A. Hauser · 2009 · Springer eBooks
82. Effect of low versus high frequency stimulation on freezing of gait and other axial symptoms in Parkinson patients with bilateral STN DBS: a mini-review
    Tao Xie, Mahesh Padmanaban, Lisa Bloom, Ellen MacCracken, Breanna Bertacchi, Abraham H. Dachman, Peter C. Warnke · 2017 · Translational Neurodegeneration
83. Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
    Martin Regensburger, Chi Wang Ip, Zacharias Kohl, Christoph Schrader, Peter P. Urban, Jan Kassubek, Wolfgang H. Jost · 2023 · Journal of Neural Transmission
84. Long-term outcomes following deep brain stimulation for Parkinson’s disease
    Frederick L. Hitti, Ashwin G. Ramayya, Brendan McShane, Andrew I. Yang, Kerry A. Vaughan, Gordon H. Baltuch · 2019 · Journal of neurosurgery
85. Genetics of Parkinson’s disease and related disorders
    Pei-Lan Zhang, Yan Chen, Chen-Hao Zhang, Yuxin Wang, Pedro Fernández-Fúnez · 2017 · Journal of Medical Genetics
86. Cognitive–behavioural therapy for non-motor symptoms of Parkinson's disease: a clinical review
    Ivan G. Koychev, David Okai · 2017 · Evidence-Based Mental Health
87. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease
    Françoise J. Siepel, Kolbjørn Brønnick, Jan Booij, Bernard M. Ravina, Alexander V. Lebedev, Joana B. Pereira, Renate Grüner, Dag Aarsland · 2014 · Movement Disorders
88. Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter
    Karl Strecker, Florian Wegner, Swen Hesse, Georg‐Alexander Becker, Marianne Patt, Philipp Meyer, Donald Lobsien, Johannes Schwarz, Osama Sabri · 2010 · Journal of Neurology
89. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression
    COPPADIS Study Group, Diego Santos‐García, Pablo Mir, Esther Cubo, Lydia Vela, María Rodríguez‐Oroz, Marı́a José Martı́, José Matías Arbelo, Jon Infante, Jaime Kulisevsky et al. · 2016 · BMC Neurology
90. Quality of life, health status and caregiver burden in Parkinson's disease: relationship to executive functioning
    Aleksandra Kudlicka, Linda Clare, John Vincent Hindle · 2013 · International Journal of Geriatric Psychiatry
91. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD
    Tao Xie, Lisa Bloom, Mahesh Padmanaban, Breanna Bertacchi, Wenjun Kang, Ellen MacCracken, Abraham H. Dachman, Julie Vigil, David I. Satzer, Cindy Zadikoff et al. · 2018 · Journal of Neurology Neurosurgery & Psychiatry
92. Animal models of Parkinson’s disease: a guide to selecting the optimal model for your research
    Joana Lama, Yazead Buhidma, Edward J. R. Fletcher, Susan Duty · 2021 · Neuronal Signaling
93. Nonmotor Manifestations in Parkinson Disease
    Óscar Bernal-Pacheco, Natlada Limotai, Criscely L. Go, Hubert H. Fernandez · 2012 · The Neurologist
94. Palliative care for Parkinson’s disease: A summary of the evidence and future directions
    Edward William Richfield, Edward JS Jones, Jane Alty · 2013 · Palliative Medicine
95. Nanocarrier for the Transdermal Delivery of an Antiparkinsonian Drug
    Adnan Azeem, Farhan Jalees Ahmad, Roop Kishan Khar, Sushama Talegaonkar · 2009 · AAPS PharmSciTech
96. Delineating nonmotor symptoms in early Parkinson's disease and first‐degree relatives
    Fahd Baig, Michael Lawton, Michal Rolinski, Claudio Ruffmann, Kannan A. Nithi, Samuel G. Evetts, Hugo J. R. Fernandes, Yoav Ben‐Shlomo, Michele T.M Hu · 2015 · Movement Disorders
97. Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, WhereasS-MDMA Extends Duration of ON-Time
    Philippe Huot, Tom H. Johnston, Katie D. Lewis, James B. Koprich, M. Gabriela Reyes, Susan Helen Fox, Matthew Piggott, Jonathan M. Brotchie · 2011 · Journal of Neuroscience
98. Parkinson Disease
    Teri Capriotti, Kristina Terzakis · 2016 · Home Healthcare Now
99. The serotonergic system in motor and non-motor manifestations of Parkinson’s disease
    P. Huot, S. Fox · 2013 · Experimental Brain Research
100. Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions
     Lazzaro di Biase, Pasquale Maria Pecoraro, Simona Paola Carbone, Maria Letizia Caminiti, Vincenzo Di Lazzaro · 2023 · Journal of Clinical Medicine